Gepotidacin (Blujepa®): A First-in-Class Triazaacenaphthylene Topoisomerase Inhibitor for Uncomplicated Urinary Tract Infections and Emerging Antimicrobial Resistance

Moultrie, GA

The emergence of multidrug-resistant uropathogens, notably fluoroquinolone- and trimethoprim-sulfamethoxazole-resistant Escherichia coli, has narrowed the therapeutic options available for management of uncomplicated urinary tract infections (uUTIs). Gepotidacin, a triazaacenaphthylene, inhibitor of bacterial type II topoisomerases recently approved by FDA (2025) for the treatment of uUTIs in adult females. Here, we are presenting the available data on gepotidacin’s structure-activity relationships (SAR), mechanism of action (MOA), pharmacokinetic and pharmacodynamic (PK/PD), resistance, and adverse effects. In the EAGLE-2 and EAGLE-3 Phase III trials, gepotidacin met the pre-specified non-inferiority criterion against nitrofurantoin in adult women with uUTI. Structurally, gepotidacin’s triazaacenaphthylene scaffold incorporates three nitrogen atoms within a fused tricyclic ring, with a critical C-3 basic side chain and defined stereocenters that are essential for high-affinity binding at the NBTI (Novel Bacterial Topoisomerase Inhibitor) pocket, which is the key SAR determinants distinguishing it from all prior antibiotic classes. Mechanistically, gepotidacin inhibits both DNA gyrase and topoisomerase IV, which is topographically distinct from the quinolone drug-binding site, conferring retained in vitro activity against fluoroquinolone-resistant isolates and plasmid-mediated quinolone resistance (PMQR) determinants. Pharmacokinetically, gepotidacin reached peak plasma level within 1.5 to 3 hours; urinary drug concentrations substantially exceed plasma levels, driving efficacy at the site of infection. Dose selection was guided by PK/PD modeling constrained to plasma concentrations below 14 µg/mL, the threshold above which QTc prolongation and acetylcholinesterase (AChE) inhibition-related cholinergic effects have been observed in clinical studies. Taken together, Gepotidacin represents a clinically meaningful therapeutic advance for uUTI management, providing an orally available agent with a novel mechanism and demonstrated efficacy against resistant uropathogens. Its cardiac and cholinergic safety profile requires careful patient selection. Continued post-marketing surveillance and resistance monitoring are warranted to define its long-term role within antimicrobial stewardship programs.